On this episode of Translating Proteomics, co-hosts Parag Mallick and Andreas Huhmer of Nautilus Biotechnology discuss how clinical researchers can leverage proteomics for drug development. Some of the themes covered in this episode include:

· Proteomics and pre-clinical models

· How proteomics can drive patient selection

· Choosing the right end points in clinical trials

Chapters

00:00 – 01:06 – Introduction

01:06 – 06:51 – Proteomics in pre-clinical studies

06:51 – 11:40 – The importance of choosing the right model for preclinical work

11:40 – 17:10 – How proteomics is used in Phase I/II clinical trials

17:10 – 19:29 – Proteomics tools in patient selection

19:29 – 24:33 – Useful information that we get from proteomics that we can’t get from genomics or transcriptomics

24:33 – 28:14 – Proteomics in Phase III clinical trials and picking the best indications of drug efficacy

28:14 – 29:19 - Understanding why clinical trials fail

29:19 – End - Outro

Resources

• The National Cancer Institute’s webpage covering how clinical trials work
• Preprint on the miBrain model - An example of a new in vitro brain model
• Geary et al., 2021 - Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials
• Wasko et al., 2024 - Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
• The NCI-MATCH trail: Lessons for precision oncology – Report on a large-scale trial using genomic biomarkers to match cancer patients to treatments
• Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer – Study using proteomics to understand mechanisms of resistance to a cancer drug